Biopharmaceutical company, Sucampo Pharmaceuticals, has announced the publication of a study in PLOS ONE that confirms the composition of VTS-270, which is currently under investigation for the treatment of Niemann-Pick Disease Type C1 (NPC-1).
Digital fingerprint
In the research, VTS-270 — a 2-hydroxypropyl-beta-cyclodextrin HPβCD) product — was demonstrated to have a low degree of consistently specific hydroxypropylation, or degree of substitution (DS), as well as a low level of doubly charged hetero-dimers as seen through an ion mobility false colour representation, or heat map. The analysis was based on ion distribution and abundance profiles using mass spectrometry methodology as a means for assessing key molecular activity.
“We are continuing to advance the science around VTS-270 as a potential treatment for NPC,” said Peter Kiener D. Phil, chief scientific officer of Sucampo. “These study results further support the specific compositional fingerprint and purity of VTS-270 that distinguishes it from other HPβCD mixtures. The defined and reproducible fingerprint is likely inextricably linked to the specific potential clinical efficacy and safety of VTS-270.”